Submit Content
Get the latest delivered to your inbox
Privacy Policy

Biogen Receives Gold Class Distinction in S&P Global Sustainability Yearbook

Published 02-18-22

Submitted by Biogen

Biogen was recently included in S&P Global's Sustainability Yearbook 2022, which assessed over 7,500 companies in the 2021 Corporate Sustainability Assessment (CSA). Only 716 companies with top scores made it into the Yearbook this year.

Earning S&P Global’s Gold Class Distinction is the culmination of significant work by our colleagues across the world – from Healthy Climate, Healthy Lives to the implementation of our DE&I strategy.

We are honored to be recognized in this year’s Sustainability Yearbook.

See the full Sustainability Yearbook 2022

Biogen Logo

Biogen

Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology and pain. We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media - Twitter, LinkedIn, Facebook, YouTube.

More from Biogen

Join today and get the latest delivered to your inbox